top of page


Cancer cells upregulate their antioxidant capacity and redox-responsive signaling pathways. A promising therapeutic approach is to increase the reactive oxygen species (ROS) to levels incompatible with tumor cell survival. Mitochondrial peroxiredoxin 3 (PRX3) plays a significant role in detoxifying ROS. Targeting PRX3 with RSO-021 elicits significant tumor cell death in preclinical and clinical studies.

PRX3-TS Model_NEW.png

We utilize advanced in vitro and in vivo tumor models to evaluate tumor cell metabolism and response to therapeutic intervention. Using biochemical, genetic, and phenotypic assays we are identifying the next generation of targeted therapies for aggressive cancers.


Life-Changing Partnerships

A collaborative approach to discover the next generation of cancer therapy involving a diverse multi-disciplinary team and innovative business partnerships.

azierta logo 1.png

Malignancies of interest with significant unmet medical need

We act with urgency to bring new medicines to patients and their families.

Target Cancers

Mesothelioma is a rare type of cancer that develops in the thin layer of tissue that covers most of your internal organs, called the mesothelium. Currently there is no cure for Mesothelioma. We are investigating mitochondrial metabolism in mesothelioma and have identified promising new compounds that selectively kill tumor cells. More information can be found on the CDC site.

Pleural Effusion

The pleura is a thin membrane that lines the surface of your lungs and the inside of your chest wall. Pleural effusion happens when an unusual amount of fluid builds up around the lungs. A variety of medical conditions can lead to this happening. If cancer grows in the pleural space, it causes a "malignant pleural effusion." 

Ovarian Cancer

Ovarian cancer is a disease that originates either in the ovaries or fallopian tubes and often spreads locally to the peritoneum. In the past decade many new therapies have been developed for ovarian cancer treatment, but unmet medical need still remains for patients with peritoneal spread of the malignancy.  More information can be found on the CDC site.

bottom of page